Why the study?
Do proteomic and metabolomic predictive models improve risk prediction for major clinical outcomes in patients with type 2 diabetes compared to the SCORE2-Diabetes clinical model?
Population
Individuals with Type 2 Diabetes (T2D) from the UK Biobank
Comparison
LASSO-based predictive models using proteomic… vs SCORE2-Diabetes clinical model
Design
Cohort
Authors
Loading...
A simplified panel of 200 proteins significantly improves the prediction of multisystem complications in type 2 diabetes compared to standard clinical models like SCORE2-Diabetes.
Do proteomic and metabolomic predictive models improve risk prediction for major clinical outcomes in patients with type 2 diabetes compared to the SCORE2-Diabetes clinical model?
A simplified panel of 200 proteins significantly improves the prediction of multisystem complications in type 2 diabetes compared to standard clinical models like SCORE2-Diabetes.
Hongqiang Zhang (2026) studied this question.